Literature DB >> 16368048

Comparative characterisation of a commercial human chorionic gonadotrophin extracted from human urine with a commercial recombinant human chorionic gonadotrophin.

R Bassett1, C De Bellis, L Chiacchiarini, D Mendola, E Micangeli, K Minari, L Grimaldi, M Mancinelli, R Mastrangeli, R Bucci.   

Abstract

BACKGROUND: A commercial preparation of recombinant human chorionic gonadotrophin (r-hCG, Ovitrelle) was launched in 2001. Generally, hCG is available in two formats: human chorionic gonadotrophin (u-hCG), derived from the urine of pregnant females, and r-hCG produced by DNA based biotechnology.
METHOD: The analytical characteristics of a highly purified u-hCG (Gonasi HP) were assessed and compared, for the first time, with the recombinant derived r-hCG (Ovitrelle). Gonasi HP is produced by extracting and purifying hCG from urine to obtain a specific bioactivity of 5000 IU/mg protein. Ovitrelle is produced via a recombinant derived mammalian cell line and purified to obtain a specific activity of 26 000 IU/mg. RESULTS AND
CONCLUSION: It has been documented that commercially available u-hCG preparations can contain a number of urine derived protein contaminants as well as hCG related metabolites. This is also the case for Gonasi HP, where hCG related molecules and other proteins were found to be present, including epidermal growth factor (EGF) and eosinophil derived neurotoxin (EDN). It was also demonstrated that this preparation contained high levels of oxidised hCG. r-hCG was confirmed to be essentially intact hCG, free from contaminant proteins and with very low levels of oxidised hCG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16368048     DOI: 10.1185/030079905X75005

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

1.  Human chorionic gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice.

Authors:  L-Y Khil; H-S Jun; H Kwon; J K Yoo; S Kim; A L Notkins; J-W Yoon
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

2.  Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free β-subunit, and β-subunit core fragment in urine.

Authors:  Getachew A Woldemariam; Anthony W Butch
Journal:  Clin Chem       Date:  2014-06-04       Impact factor: 8.327

3.  Replacement of Male Mini-Puberty.

Authors:  Dimitrios T Papadimitriou; Dionysios Chrysis; Georgia Nyktari; George Zoupanos; Eleni Liakou; Anastasios Papadimitriou; George Mastorakos
Journal:  J Endocr Soc       Date:  2019-05-09

4.  Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy.

Authors:  Chiara Dallagiovanna; Laura Mensi; Luca Di Gesaro; Irene La Vecchia; Marco Reschini
Journal:  Drugs Context       Date:  2022-01-26

Review 5.  Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation.

Authors:  P E Levi Setti; C Alviggi; G L Colombo; C Pisanelli; C Ripellino; S Longobardi; P L Canonico; G De Placido
Journal:  J Endocrinol Invest       Date:  2014-12-06       Impact factor: 4.256

6.  Clinical outcomes of assisted reproductive technology treatment by using a self-injection of recombinant human chorionic gonadotropin as the final maturation trigger.

Authors:  Koji Nakagawa; Midori Oba; Kaori Ehara; Nozomi Ishigaki; Nao Ino; Akiko Itakura; Ryo Tsutsumi; Katsuki Nakao; Yuko Ojiro; Rikikazu Sugiyama
Journal:  Reprod Med Biol       Date:  2018-03-23

7.  Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects.

Authors:  Jin Wang; Tianli Yang; Hekun Mei; Xueming Yu; Hongmei Peng; Rui Wang; Yun Cai
Journal:  Drug Des Devel Ther       Date:  2020-01-29       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.